SCHEMBL5482013

SCHEMBL5482013

Cn1c(Cl)nc2c1NC(=O)C2(c1ccc(N)cc1)c1ccc(N)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 13/20 0.34
HSD11B2 P80365 1/20 0.33
HTR6 P50406 1/20 0.33
CYP3A4 P08684 2/20 0.31
CYP17A1 P05093 1/20 0.31
CYP11A1 P05108 1/20 0.31
TBXAS1 P24557 1/20 0.31
PMP22 Q01453 1/20 0.31
PDE4D Q08499 1/20 0.31
PDE3A Q14432 1/20 0.31
NFKB1 P19838 1/20 0.31
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
GAA P10253 1/20 0.30
PKM P14618 1/20 0.30
ALOX15 P16050 1/20 0.30
RAB9A P51151 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483177 0.69 LMNA (0.37) CYP19A1HTR6CYP3A4CYP17A1CYP11A1
SCHEMBL5481837 0.69 RAB9A (0.33) KDM4ENPC1ALDH1A1TP53PKM
SCHEMBL5481736 0.63 CYP19A1 (0.36) CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1
SCHEMBL9342160 0.57 LMNA (0.73) CYP19A1KDM4EALDH1A1GAA
SCHEMBL17054772 0.56 MEN1 (0.55) CYP19A1
SCHEMBL17054770 0.56 MEN1 (0.55) CYP19A1
SCHEMBL17055125 0.56 MEN1 (0.55) CYP19A1
SCHEMBL5481733 0.55 LMNA (0.37) CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1
SCHEMBL6232931 0.55 SMN1; SMN2 (0.58) NFKB1KDM4ENPC1ALDH1A1TP53
SCHEMBL6230772 0.55 SMN1; SMN2 (0.58) KDM4ENPC1ALDH1A1TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 CYP19A1 1589/4885HSD11B2 3098/4885HTR6 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.